ATE321856T1 - Humane rezeptortyrosinkinase - Google Patents
Humane rezeptortyrosinkinaseInfo
- Publication number
- ATE321856T1 ATE321856T1 AT99955501T AT99955501T ATE321856T1 AT E321856 T1 ATE321856 T1 AT E321856T1 AT 99955501 T AT99955501 T AT 99955501T AT 99955501 T AT99955501 T AT 99955501T AT E321856 T1 ATE321856 T1 AT E321856T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine kinase
- human receptor
- receptor tyrosine
- well
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Processing Of Solid Wastes (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8895898P | 1998-06-11 | 1998-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE321856T1 true ATE321856T1 (de) | 2006-04-15 |
Family
ID=22214506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99955501T ATE321856T1 (de) | 1998-06-11 | 1999-06-08 | Humane rezeptortyrosinkinase |
Country Status (8)
Country | Link |
---|---|
US (2) | US6969596B2 (de) |
EP (1) | EP1084245B1 (de) |
JP (1) | JP2002517241A (de) |
AT (1) | ATE321856T1 (de) |
AU (1) | AU4278299A (de) |
DE (1) | DE69930662T2 (de) |
ES (1) | ES2262347T3 (de) |
WO (1) | WO1999064589A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396810B1 (en) | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
WO2000073469A2 (en) * | 1999-05-28 | 2000-12-07 | Sugen, Inc. | Protein kinases |
WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
AR028424A1 (es) * | 2000-05-10 | 2003-05-07 | Bayer Corp | Metodo para regular la angiogenesis utilizando proteina ryk |
WO2002087619A1 (fr) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
US20050239088A1 (en) * | 2003-05-16 | 2005-10-27 | Shepard H M | Intron fusion proteins, and methods of identifying and using same |
US7741070B2 (en) * | 2003-12-24 | 2010-06-22 | Massachusetts Institute Of Technology | Gene targets for enhanced carotenoid production |
US20090222931A1 (en) * | 2004-05-13 | 2009-09-03 | Tsinghua University | Novel identified oncogene with kinase-domain (nok) |
JP2008506366A (ja) * | 2004-05-14 | 2008-03-06 | レセプター バイオロジックス インコーポレイテッド | 細胞表面受容体アイソフォームならびにその同定および使用方法 |
WO2006042002A2 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
GB0807018D0 (en) * | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
EP2504024A2 (de) * | 2009-09-27 | 2012-10-03 | Ruhr-Universität Bochum | Verfahren zur therapie und diagnose von morbus alzheimer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5684136A (en) * | 1992-05-18 | 1997-11-04 | Genentech, Inc. | Chimeric hepatocyte growth factor (HGF) ligand variants |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
EP0758196A4 (de) * | 1994-05-05 | 1999-05-06 | Univ Pennsylvania | Zusammensetzungen und verfahren zur tumorbehandlung |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
AU2066797A (en) * | 1996-03-21 | 1997-10-10 | Sugen, Inc. | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
-
1999
- 1999-06-08 AT AT99955501T patent/ATE321856T1/de not_active IP Right Cessation
- 1999-06-08 ES ES99955501T patent/ES2262347T3/es not_active Expired - Lifetime
- 1999-06-08 WO PCT/GB1999/001798 patent/WO1999064589A1/en active IP Right Grant
- 1999-06-08 JP JP2000553579A patent/JP2002517241A/ja active Pending
- 1999-06-08 DE DE69930662T patent/DE69930662T2/de not_active Expired - Fee Related
- 1999-06-08 AU AU42782/99A patent/AU4278299A/en not_active Abandoned
- 1999-06-08 EP EP99955501A patent/EP1084245B1/de not_active Expired - Lifetime
-
2002
- 2002-01-07 US US10/040,884 patent/US6969596B2/en not_active Expired - Fee Related
-
2005
- 2005-05-05 US US11/122,590 patent/US20050208566A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999064589A1 (en) | 1999-12-16 |
DE69930662D1 (de) | 2006-05-18 |
DE69930662T2 (de) | 2006-12-28 |
ES2262347T3 (es) | 2006-11-16 |
JP2002517241A (ja) | 2002-06-18 |
AU4278299A (en) | 1999-12-30 |
EP1084245A1 (de) | 2001-03-21 |
US6969596B2 (en) | 2005-11-29 |
US20030078222A1 (en) | 2003-04-24 |
EP1084245B1 (de) | 2006-03-29 |
US20050208566A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE321856T1 (de) | Humane rezeptortyrosinkinase | |
DK0813545T3 (da) | Nukleotid- og proteinsekvenser af hvirveldyrs-Serrate-gener og fremgangsmåde baseret derpå | |
NO20065528L (no) | Forbindelser som fremmer vevsvekst. | |
EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
DK0861261T3 (da) | Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå | |
ITMI20010562A1 (it) | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari | |
DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
DE69028101T2 (de) | Melaninkonzentrierende hormone und dns die diese expremieren | |
ATE337339T1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
BRPI0414793A (pt) | uso do fator anti-secretor | |
WO2000060062A3 (en) | Human signal transduction serine/threonine protein kinase | |
EA038283B1 (ru) | Способ лечения или предупреждения остеоартрита | |
ATE285794T1 (de) | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien | |
WO2004043373A3 (en) | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
IL136306A (en) | Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder | |
DE69829995D1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
ATE300554T1 (de) | Bindegewebe-wachstumsfaktor 3. | |
BR0308040A (pt) | Composições farmacêuticas e cosméticas compreendendo plgf-1 | |
Wirtz et al. | In vivo and in vitro noncovalent association of excised alpha 1 (I) amino-terminal propeptides with mutant pN alpha 2 (I) collagen chains in native mutant collagen in a case of Ehlers-Danlos syndrome, type VII. | |
ATE491028T1 (de) | Transformierender wachstumsfaktor alpha hii | |
DK0820308T3 (da) | Konjugat til behandling af inflammatoriske sygdomme | |
Dimaline et al. | A novel family of VIP-like peptides from the dogfish scyliorhinus canicula. | |
ATE262343T1 (de) | Verwendung von gnrh analogen zur behandlung von schizophrenie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |